Compare Novo Nordisk A/S (NVO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Payoneer Global Inc — how do they compare? Novo Nordisk A/S trades at $45.05 (market cap $198.57B), while Payoneer Global Inc trades at $7.11 (market cap $2.41B). The key difference: Novo Nordisk A/S is far larger — about 82.4× Payoneer Global Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| NVO | PAYO | |
|---|---|---|
Market Cap | $198.57B | $2.41B |
Sector | Health | Technology |
52-Week High | $63.98 | $7.18 |
52-Week Low | $35.29 | $4.27 |
Enterprise Value | $213.37B | $2.15B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a market cap of approximately $2.3 billion. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $821 million in 2025 with a 79.4% gross margin, though net income margin declined to 5.83%. Recent news highlights the pending acquisition by Nuvei for $7.40 per share, with multiple law firms investigating the fairness of the deal price.
The acquisition offer at $7.40 provides near-term upside potential, but investor sentiment is cautious due to legal scrutiny. Long-term growth prospects remain positive with expanding global operations, though earnings volatility and competitive pressures present risks. Analyst consensus is bullish with 60% buy ratings, but the stock faces execution risks in integrating the India tech hub and maintaining B2B growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
